- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02457117
A Multi-Institutional Registry for CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Radiotherapy for breast cancer is delivered using several whole breast and partial breast approaches. The optimal approach is unknown. The utilization of partial breast irradiation is growing due to the convenience of fewer fractions versus fifteen- thirty treatments required with conventional or hypofractionated whole breast radiation therapy.
Early results with partial breast techniques are promising, showing similar cancer control and toxicity. There is a large body of mature Phase I/II and preliminary Phase III data available exploring the replacement of WBI with an accelerated course of radiation therapy restricted to the region around the tumor bed (accelerated Partial Breast Irradiation, aPBI) using a variety of techniques. For appropriately selected patients treated with modern techniques, the results are encouraging and the techniques have been shown to be safe, tolerable, and highly reproducible with outcomes similar to WBI.
Currently, there is limited data assessing the quality of life, cosmetic and oncologic outcomes following stereotactic partial breast irradiation in a large patient population. Our study will be the first essential step in aggregating the outcomes of patients undergoing this type of external beam irradiation in a large patient population.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Olusola Obayomi-Davies, M.D.
- Phone Number: 6104465860
- Email: olusola.obayomi-davies@crozer.org
Study Contact Backup
- Name: Michael Repka, M.D.
- Phone Number: 2024443320
- Email: michael.c.repka@gunet.georgetown.edu
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20008
- Recruiting
- Georgetown University Hospital
-
Contact:
- Olusola OBAYOMI-DAVIES, M.D
- Phone Number: 202-444-3320
- Email: olusola.obayomi-davies@medstar.net
-
Principal Investigator:
- Olusola Obayomi-Davies, M.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects are eligible to participate in the registry if they receive CK-SAPBI in 5 fractions within 12 weeks of surgery and sign an institution specific consent form.
Additionally, subjects will be considered standard risk and optimal for CK-SAPBI if they meet the following criteria:
- Newly diagnosed AJCC (seventh edition) Stage 0 or I breast cancer.
- On histological examination, the tumor must be DCIS or invasive non-lobular carcinoma of the breast
- Surgical treatment of the breast must have been wide excision, lumpectomy or partial mastectomy
- Age 50 years or greater
- ER positive
- PR positive
- Her2 negative (IHC 0-1+; for IHC 2+, FISH must be non-amplified)
- Subjects with invasive tumors should undergo axillary sentinel lymph node evaluation or axillary lymph node dissection.
- Negative inked surgical margins of excision or re-excision, clear of invasive tumor and DCIS by at least 2 mm
- Negative post-excision or post-reexcision mammography if cancer presented with malignancy-associated microcalcifications with no remaining suspicious calcifications in the breast before radiotherapy. Alternatively, a specimen radiograph can be obtained showing all the suspicious calcifications.
- No involved axillary lymph nodes, N0(i+) allowed
- Target lumpectomy cavity/whole breast reference volume must be <30% based on treatment planning CT
Exclusion Criteria:
- -Patients with invasive lobular carcinoma or nonepithelial breast malignancies such as sarcoma or lymphoma.
- Patients with tumors greater than 2 cm
- Patients with surgical margins which cannot be microscopically assessed or not cleared by at least 2mm at pathological evaluation.
- Patients with multicentric carcinoma or with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy. Breast MRI will be required to exclude multicentric disease and additional suspicious areas will require biopsy to exclude malignancy.
- Patients with involved axillary nodes.
- Patients with collagen vascular diseases (active).
- Patient with known deleterious BRCA1/2 mutations or known mutations in other high penetrance genes (TP53, STK11, PTEN, CDH1)
- Patients with prior ipsilateral breast irradiation.
- Patients with prior ipsilateral thoracic irradiation.
- Patients with Paget's disease of the nipple.
- Patients with diffuse suspicious microcalcifications.
- Patients with suspicious microcalcifications remaining on the post-excision mammogram.
- Patients receiving (neo)adjuvant systemic therapy other than hormonal therapy
- Patients with oncoplastic reconstruction and absence of surgical clips
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Other
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In breast failure
Time Frame: 5 years
|
To evaluate the in-breast local failure (Ipsilateral breast events) and patterns of in-breast failure following CK-SAPBI
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cosmesis
Time Frame: 5 years
|
Treatment related Cosmesis based on the Harvard Cosmesis Scale
|
5 years
|
Regional Recurrence
Time Frame: 5 years
|
Regional recurrence free interval defined as time from end of radiation treatment to the diagnosis of disease in the regional lymph nodes
|
5 years
|
Distant Recurrence
Time Frame: 5 years
|
Distant disease free interval defined as the time from end of radiation treatment to first diagnosis of distant disease, regardless of the occurrence of any intervening local or regional failure, contralateral breast cancer, or non-breast second primary cancer
|
5 years
|
Adverse reactions
Time Frame: 5 years
|
Toxicity from treatment based on CTCAE version 4.0
|
5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2015-0098
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)
-
Georgetown UniversityTerminatedBreast Cancer | DCIS | Invasive Ductal CarcinomaUnited States
-
The Netherlands Cancer InstituteInstitut CurieTerminatedBreast Cancer | Neoplasms, Breast | Cancer of the BreastFrance, Netherlands, Portugal, Spain
-
Georgetown UniversityWithdrawnBreast CancerUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Unknown
-
Cancer Institute and Hospital, Chinese Academy...RecruitingBreast Neoplasms | Neoplasm Recurrence, LocalChina
-
National Institute of Oncology, HungaryActive, not recruitingBreast Cancer | Radiation Toxicity | Side EffectsHungary
-
Virginia Commonwealth UniversityRecruiting
-
University of Erlangen-Nürnberg Medical SchoolCompletedBreast CancerGermany, Austria
-
Rocky Mountain Cancer CentersRecruiting
-
Washington University School of MedicineCompletedBreast NeoplasmsUnited States